Jefferies analyst Maury Raycroft believes both events will be stock-moving, skewed to the upside
Ahead of BeyondSpring’s (BYSI) Prescription Drug User Fee Act, or PDUFA, date for its plinabulin for chemotherapy-induced neutropenia, or CIN, Jefferies analyst Maury Raycroft said he expects the event to be stock-moving and thinks “expectations for approval have come in.” He sees the stock going up over 70% if the treatment is approved. Meanwhile Calliditas Therapeutics’ (CALT) nefecon PDUFA date for immunoglobulin A nephropathy, or IgAN, is also approaching, and Raycroft believes there is a “good chance” of approval based on the totality of the data.
BEYONDSPRING PLINABULIN PDUFA: BeyondSpring’s plinabulin PDUFA deadline for CIN is set for Tuesday, November 30, and Jefferies analyst Maury Raycroft expects the event to be stock-moving. He thinks “expectations for approval have come in,” but the analyst currently estimates potential for the stock to be up over 70%, if approved, and down 40%, if a Complete Response Letter comes from the FDA. The event is “interesting,” he argued, because there is readthrough to BeyondSpring’s second filing opportunity in non-small cell lung cancer, which is based on recent Phase 3 data. His view is that plinabulin should get approved based on the total data package demonstrating plinabulin’s benefit, with some additional confidence coming from the drug having Breakthrough Therapy Designation.
To see the rest of the story Click Here.